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Summary:
which may compromise the ability to mobilize hematopoietic progenitor cells and may result in delayed hematopoietic recovery, in particular thrombopoiesis, after myeloIn 29 consecutive heavily pretreated stage IV breast cancer patients, we analyzed patient factors and in vitro ablative therapy. 2, 7, 12 In prior studies, the number of mononuclear cells, CD34
+ cells, or CFU-GM have been characteristics of peripheral blood progenitor cell (PBPC) collections that might correlate with the speed used with variable degrees of success to predict reliable engraftment of peripheral blood progenitor cells after highof hematopoietic recovery after autologous transplantation. PBPC collections were assessed for total number dose chemotherapy.
2, [12] [13] [14] [15] [16] [17] [18] [19] Twenty-nine heavily pre-treated stage IV breast cancer of mononuclear cells infused/patient weight in kg and hematopoietic progenitor cell content using in vitro patients, who received peripheral blood progenitor cells as sole hematopoietic support after high-dose chemotherapy colony-forming assays. In these patients, who received PBPC as the sole hematopoietic support after myelowere the subject of this analysis. We observed significant variation in the tempo of platelet recovery and found that ablative chemotherapy, the number of erythroid burstforming units (BFU-E) infused correlated significantly the number of BFU-E infused accurately predicted time to both neutrophil and platelet recovery. with both time to neutrophil (P = 0.008) and platelet (P = 0.0001) recovery and was a better predictor of hematopoietic recovery than number of CFU-GM administered. By day 75 after transplantation, six patients with Patients and methods poor BFU-E yields failed to engraft platelets. Our data suggest that the number of BFU-E infused correlate
Patient eligibility with time to hematopoietic engraftment and may
Between May 1991 and September 1994, 29 patients with predict failure of platelet engraftment in heavily prestage IV breast cancer underwent leukapheresis after treated patients.
administration of either recombinant hematopoietic growth Keywords: BFU-E; hematopoietic recovery; peripheral factors (G-CSF and/or GM-CSF) or standard-dose chemoblood progenitor cells; breast cancer therapy followed by hematopoietic growth factors, using previously published methods. 20 Eligibility criteria included advanced breast cancer, age Ͻ66 years, ECOG performPeripheral blood progenitor cells are used with increasing ance status of 0-1, adequate cardiac, pulmonary, renal, hepfrequency for hematopoietic support in breast cancer atic function, and an absolute neutrophil count (ANC) patients undergoing high-dose chemotherapy and autologgreater than 1.2 ϫ 10 9 /l and platelet count greater than ous transplantation.
1-4 Hematopoietic growth factors either 100 ϫ 10 9 /l, in patients previously given standard-dose alone or after recovery from myelosuppressive chemochemotherapy. Presence of tumor cells in the bone marrow therapy enhance the concentration of circulating hemato-(determined histologically) or peripheral blood (determined poietic progenitor cells six-to 60-fold and allow collection by immunohistochemical staining) did not exclude a patient via leukapheresis procedures for reinfusion. 5, 6 Advantages from treatment. 9 All patients were treated at the Ireland of peripheral blood progenitor cells collected in this manner Cancer Center, University Hospitals of Cleveland on Instiinclude more rapid engraftment and a significantly lower tutional Review Board-approved protocols and gave written incidence of tumor contamination compared to autologous informed consent. bone marrow. [7] [8] [9] [10] [11] Many stage IV breast cancer patients have previously
Leukapheresis procedures received extensive cytotoxic chemotherapy and/or radiation In the patients who underwent mobilization procedures using hematopoietic growth factors alone, GM-CSF Oaks, CA, USA) at a dose of 5-7.5 g/kg, or the combi-nation, were given by daily subcutaneous injection for a centration of 5 ϫ 10 4 cells/ml suspended in a mixture of Iscove's modified Dulbecco's medium with 30% selected minimum of 3 consecutive days before beginning peripheral blood progenitor cell collections. In comparison, for lots of bovine calf serum (Hyclone Laboratories, Logan, UT, USA), 10 mmol/l hemin (Sigma Chemicals, St Louis, leukaphereses performed after recovery from conventionaldose chemotherapy, hematopoietic growth factor treatment MO, USA), 100 U/ml recombinant human interleukin-3 (rhIL-3), 200 U/ml rhGM-CSF (Sandoz Pharmaceutical, was initiated within 2 days after completion of chemotherapy and was continued until peripheral blood progenitor East Hanover, NJ, USA), and 4 U/ml recombinant human erythropoietin (rh-EPO) (Amgen, Thousand Oaks, CA, cell collections were finished. Leukaphereses were performed using a COBE Spectra (COBE Laboratories, Lake-USA). After growth in culture for 14 days, colonies of greater than 50 cells were classified as CFU-GM, BFU-E wood, CO, USA) and a minimum of 10 liters of blood were processed over 2-3 h during each apheresis session accordor CFU-GEMM, and counted under an inverted phase microscope. ing to previously published methods. 21 Patients underwent leukaphereses via multi-lumen central venous pheresis catheters daily or approximately every other day until a
Statistical analysis minimum of 8 × 10 8 mononuclear cells/kg or 6 × 10 4 CFU-GM/kg patient weight were collected. Patients with inad-
The number of days to achieve an absolute neutrophil count у0.5 ϫ 10 9 /l and an unsupported platelet count equate numbers of CFU-GM progenitors underwent additional leukaphereses before receiving myeloablative у20 ϫ 10 9 /l was correlated with total number (per kg) of mononuclear cells, CFU-GM, and BFU-E infused using therapy. The cellular concentrate was cryopreserved in 10% DMSO using a controlled rate freezer and stored in liquid Cox proportional hazards survival methods. This method was chosen since it allowed for inclusion of patients who nitrogen according to previously published methods. 22 did not achieve platelet engraftment. Other variables considered in the analyses were patient age, number of cycles Treatment plan and supportive care of chemotherapy received before leukapheresis, and tumorous bone marrow contamination. Multivariate analysis was Patients received peripheral blood progenitor cells as sole hematopoietic support after a preparative regimen consisting used to evaluate the relative importance of the CFU-GM and BFU-E on neutrophil and platelet recovery. of either carboplatin, thiotepa, and cyclophosphamide (27 patients) 23 or ifosfamide, carboplatin, and etoposide (two patients). 24 All patients were treated in single hospital rooms that received high-efficiency particulate air (HEPA) filResults tration and were given low-pathogen diets. Prophylactic antimicrobial therapy included one double-strength Patient characteristics trimethoprim-sulfamethoxazole tablet by mouth or 10 ml
The characteristics of 29 patients who received peripheral intravenously twice daily 3 days per week for Pneumocystis blood progenitor cells as sole hematopoietic support after cariini pneumonia prophylaxis and acyclovir at a dose of high-dose chemotherapy are shown in Table 1 . In general, 750 mg/m 2 daily intravenously in three divided doses. Beginning 4 h after peripheral blood progenitor cell rein- was at least 0.5 ϫ 10 9 /l. The time to achieve platelet recov- blood mononuclear cells were plated in triplicate at a con- alone using GM-CSF (n = 9), G-CSF (n = 4), or the combia Based on 27 patients.
nation of GM-CSF and G-CSF (n = 5). 20 Six patients underwent leukapheresis during recovery of blood counts after standard-dose chemotherapy followed by hematopoietic growth factors. Five patients initially had inadequate predictive value for neutrophil recovery was of borderline significance (P = 0.049 and 0.10, respectively). shows the relationship between CFU-GM and BFU-E infused and hematopoietic recovery. Although log CFUation alone, additional leukaphereses were performed using chemotherapy and hematopoietic growth factors. Only two GM correlated with log BFU-E infused (r = 0.51, P = 0.005), multivariate analysis revealed that BFU-E infused of these five patients had an improved yield of BFU-E and CFU-GM after receiving the combination of chemotherapy was the best predictor of neutrophil and platelet engraftment and that CFU-GM did not significantly and hematopoietic growth factors.
improve the ability to predict time to hematopoietic recovery once BFU-E was considered.
Predictors of hematopoietic recovery
The presence of bone marrow metastases and the number of cycles of chemotherapy received before the peripheral Twenty-nine patients who received peripheral blood progenitor cells as sole hematopoietic support after high-dose blood progenitor cell transplant did not influence hematopoietic recovery. However, older patients had significantly chemotherapy underwent a median of eight aphereses (range 5-17) yielding a median of 13.45 ϫ 10 8 mononuclear delayed platelet recovery ( Figure 2 ) (P = 0.008). Furthermore, increased patient age correlated with prolonged time cells/kg (range 7.06-23.02 ϫ 10 8 ). Collections contained a median of 14.8 ϫ 10 4 CFU-GM/kg (range 4.45-29.5) and to platelet recovery after adjusting for the number of BFU-E infused (P = 0.048). 19 ϫ 10 4 BFU-E/kg (range 6.43-116). Neutrophil recovery was prompt for all patients, with a median time to achieve Six patients failed to recover platelet counts by day 75 and three subjects never achieved platelet transfusion indean absolute neutrophil count of у0.5 × 10 9 /l of 12 days (range 9-17) after the peripheral blood progenitor cell reinpendence (Table 3 ). The median age of these patients was 52 years (range 43-56) compared to 43 years (range 24-fusion. On the other hand, the median time until platelet transfusion independence was 26 days among the 23 patients 61) for the entire population. These patients received a median of 10 cycles of chemotherapy and two regimens for who recovered by day 75, and 35 days in the entire population (n = 29), with a range between 8 and 120+ days. metastatic disease before undergoing leukaphereses, indicating that these subjects had received more extensive treatCox proportional hazards survival methods were used to analyze recovery data in order to allow for inclusion of ment than the individuals who experienced successful hematopoietic recovery. Furthermore, the six patients required patients who did not achieve platelet recovery (Table 2) . Log transformations of cell counts were used to normalize a median of 11 apheresis procedures (range 6-17) compared to a median of eight for the group of 29 patients in for the skewed distributional qualities of the three characteristics of peripheral blood progenitor cell collections order to mobilize adequate numbers of CFU-GM. Mobilization strategies included G-CSF alone for three of these including numbers of mononuclear cells, CFU-GM and BFU-E. The log total number of mononuclear cells infused patients, and GM-CSF alone for one patient. Two patients had peripheral blood progenitor cell collections using two did not predict either neutrophil or platelet recovery (P = 0.78 and 0.35, respectively). Univariate analysis using Cox mobilization strategies; in one case for inadequate numbers of progenitor cells collected using blood stimulating factors proportional hazards model demonstrated a strong correlation of log BFU-E infused with neutrophil and platelet alone and in the other since sequential mobilization strategies were specified as part of a therapeutic treatment prorecovery (P = 0.008 and 0.0001, respectively). Although log CFU-GM infused correlated with platelet recovery, the tocol. 20 One patient (UPN 5080) developed a cytomegalo- 
Discussion
Although peripheral blood progenitor cells are commonly used as hematopoietic support following high-dose chemotherapy in patients with advanced breast cancer, factors determining the engraftment potential of hematopoietic progenitor cells have not been evaluated extensively in these patients. We found that the number of BFU-E infused was superior to either CFU-GM or mononuclear cells in predicting the time to platelet and neutrophil engraftment.
In 29 patients who received peripheral blood progenitor cells as the sole hematopoietic support after high-dose chemotherapy, neutrophil recovery was prompt. Median time to achieve platelet transfusion independence, among those who recovered (n = 23), was 26 days and six patients ery in our patients compared to other series of breast cancer patients included extensive treatment before transplantation, the use of hematopoietic growth factors without virus infection at day +45, never recovered platelet counts, and subsequently succumbed to a fungal infection. Three chemotherapy for mobilization of progenitor cells in the majority of patients, and a high incidence of bone marrow of six patients had persistent or progressive bone marrow metastases after transplantation and two patients had contamination. 15, 16, 27, 28 Furthermore, administration of hematopoietic growth factors after peripheral blood prorapidly progressive disease after high-dose chemotherapy. It is of interest that UPN 5093 received a disparately low genitor cell transplantation has been associated with delayed platelet engraftment, in particular, if low numbers dose of BFU-E compared to CFU-GM and failed to engraft platelets. Each of these six patients had received a relatively of progenitor cells are infused. 15, 19, 29 In general, we found that the patients who failed to recover platelet counts were low, but believed to be an adequate, dose of CFU-GM and mononuclear cells. 2, 7, 26 older, had received more chemotherapy regimens for meta- static disease and had required more leukaphereses yielded a wide range of BFU-E as well as the significant numbers of patients who experienced delayed hemato-(median, 11 vs 8) compared to the patients who had successful platelet engraftment. However, none of these patient poiesis may explain, in part, the relationship we observed between BFU-E, a surrogate marker of stem cell function, characteristics, alone or in combination, would have predicted failure to engraft platelets for an individual patient.
and hematopoietic recovery. On the other hand, recent evidence suggesting that regulation of erythropoiesis and The observation of delayed and failed platelet engraftment prompted our group to evaluate characteristics megakaryopoiesis is linked may provide a biological explanation for our observation. [32] [33] [34] [35] [36] of the peripheral blood progenitor cell infusion that would predict prompt hematopoietic recovery. A number of invesMany patients with metastatic breast cancer have poor marrow reserve due to extensive treatment with conventigators have reported that infusing a threshold dose of CD34 + cells or CFU-GM in patients with breast cancer or tional-dose chemotherapy before undergoing peripheral blood progenitor cell collections in preparation for highlymphoma will ensure engraftment after myeloablative therapy in the majority of patients. [13] [14] [15] [16] [17] [18] In general, patients dose chemotherapy. Although it is not always possible to obtain a threshold number of CD34 + cells from these included in these studies did not receive extensive chemotherapy before undergoing peripheral blood progenitor cell patients, most will achieve successful hematopoietic recovery. Our data suggest that BFU-E may be helpful in collection. In our patients, we found that number of BFU-E infused correlated significantly with time to platelet and determining the engraftment potential of peripheral blood progenitor cell collections, particularly if there are neutrophil recovery (P = 0.0001, P = 0.008, respectively). Moreover, with one exception, all patients who received a suboptimal numbers of CD34 + cells or CFU-GM. threshold dose of 11 × 10 4 BFU-E/kg became platelet transfusion independent in a timely fashion. Although we could not establish a similar threshold number of CFU-GM, allspect, in this patient series, the number of BFU-E infused pheral blood progenitor cells by chemotherapy and granulowould have predicted graft failure for five of six patients. In our study, differences in culture techniques which
